Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lamivudine + tenofovir disoproxil fumarate
- Development stage
- Approved
- Lead developer
- Quality Chemical Industries
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Lamivudine + tenofovir disoproxil fumarate is a fixed-dose combination antiretroviral therapy developed and manufactured by Quality Chemicals Industries Limited (QCIL) for the treatment of HIV/AIDS. The formulation combines two nucleos(t)ide reverse transcriptase inhibitors (NRTIs): lamivudine (3TC), a nucleoside analogue, and tenofovir disoproxil fumarate (TDF), a nucleotide analogue. Both components target the HIV-1 reverse transcriptase enzyme, acting as chain terminators that inhibit viral DNA synthesis and replication. This small molecule combination is administered as an oral tablet and is part of QCIL's efforts to provide accessible generic HIV treatments in the African market.
- Brand names
- CimduoTemixys
- Other names
- 3TC/TDFLamivudine/Tenofovir Disoproxil Fumarate
02
Targets
Human immunodeficiency virus type 1 reverse transcriptaseHBV Pol (Hepatitis B virus polymerase)
Beyond the preview
Go deeper on lamivudine + tenofovir disoproxil fumarate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lamivudine + tenofovir disoproxil fumarate.